Efstratios M Kolibianakis

List of Publications by Year
in descending order

136	6,541	66234	71532
papers	citations	42 h-index	76 g-index

137	137	137	3265
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	In Vitro Fertilization with Single Blastocyst-Stage versus Single Cleavage-Stage Embryos. New England Journal of Medicine, 2006, 354, 1139-1146.	13.9	356
2	Cryopreservation of human embryos by vitrification or slow freezing: a systematic review and meta-analysis. Fertility and Sterility, 2008, 90, 186-193.	0.5	326
3	Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertility and Sterility, 2002, 78, 1025-1029.	0.5	323
4	Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertility and Sterility, 2006, 85, 112-120.	0.5	298
5	Live birth rates after transfer of equal number of blastocysts or cleavage-stage embryos in IVF. A systematic review and meta-analysis. Human Reproduction, 2008, 23, 91-99.	0.4	255
6	How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertility and Sterility, 2009, 91, 749-766.	0.5	196
7	Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Human Reproduction Update, 2009, 15, 613-622.	5.2	162
8	Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertility and Sterility, 2003, 79, 873-880.	0.5	156
9	Risk of spontaneous miscarriage in euthyroid women with thyroid autoimmunity undergoing IVF: a meta-analysis. European Journal of Endocrinology, 2010, 162, 643-652.	1.9	148
10	Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertility and Sterility, 2004, 82, 102-107.	0.5	137
11	Progesterone rise on the day of human chorionic gonadotropin administration impairs pregnancy outcome in day 3 single-embryo transfer, while has no effect on day 5 single blastocyst transfer. Fertility and Sterility, 2009, 91, 949-952.	0.5	136
12	Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Human Reproduction, 2010, 25, 683-689.	0.4	131
13	Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes. Human Reproduction, 2005, 20, 1541-1547.	0.4	126
14	Estimating the net effect of progesterone elevation on the day of hCG on live birth rates after IVF: a cohort analysis of 3296 IVF cycles. Human Reproduction, 2015, 30, 684-691.	0.4	126
15	Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. Human Reproduction, 2008, 24, 764-774.	0.4	119
16	Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials. Fertility and Sterility, 2013, 100, 1622-1628.e3.	0.5	116
17	Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Fertility and Sterility, 2009, 92, 667-677.	0.5	115
18	Live delivery rates in subfertile women with Asherman's syndrome after hysteroscopic adhesiolysis using the resectoscope or the Versapoint system. Reproductive BioMedicine Online, 2004, 8, 720-725.	1.1	106

#	Article	IF	Citations
19	Significantly Lower Pregnancy Rates in the Presence of Progesterone Elevation in Patients Treated with GnRH Antagonists and Gonadotrophins: A Systematic Review and Meta-Analysis. Current Pharmaceutical Biotechnology, 2012, 13, 464-470.	0.9	104
20	Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reproductive Biology and Endocrinology, 2014, 12, 17.	1.4	101
21	The luteal phase after ovarian stimulation. Reproductive BioMedicine Online, 2002, 5, 26-35.	1.1	98
22	Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertility and Sterility, 2003, 80, 464-466.	0.5	95
23	Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. Fertility and Sterility, 2008, 90, 1055-1063.	0.5	90
24	Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction, 2006, 21, 352-357.	0.4	89
25	Cryopreservation of human embryos by vitrification or slow freezing: which one is better?. Current Opinion in Obstetrics and Gynecology, 2009, 21, 270-274.	0.9	87
26	Association of estradiol levels on the day of hCG administration and pregnancy achievement in IVF: a systematic review. Human Reproduction, 2004, 19, 2446-2453.	0.4	84
27	Human chorionic gonadotropin administration vs. luteinizing monitoring for intrauterine insemination timing, after administration of clomiphene citrate: a meta-analysis. Fertility and Sterility, 2007, 87, 607-612.	0.5	84
28	Prolongation of follicular phase by delaying hCG administration results in a higher incidence of endometrial advancement on the day of oocyte retrieval in GnRH antagonist cycles. Human Reproduction, 2005, 20, 2453-2456.	0.4	79
29	Modified natural cycle for IVF does not offer a realistic chance of parenthood in poor responders with high day 3 FSH levels, as a last resort prior to oocyte donation. Human Reproduction, 2004, 19, 2545-2549.	0.4	73
30	Monozygotic twinning is not increased after single blastocyst transfer compared with single cleavage-stage embryo transfer. Fertility and Sterility, 2010, 93, 592-597.	0.5	72
31	Flexible GnRH antagonist versus flare-up GnRH agonist protocol in poor responders treated by IVF: a randomized controlled trial. Human Reproduction, 2008, 23, 1355-1358.	0.4	70
32	Regimen of ovarian stimulation affects oocyte and therefore embryo quality. Fertility and Sterility, 2016, 105, 560-570.	0.5	69
33	Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study. Reproductive BioMedicine Online, 2006, 13, 166-172.	1.1	63
34	Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders. Human Reproduction, 2015, 30, 2321-2330.	0.4	61
35	Risk of gestational diabetes mellitus in women achieving singleton pregnancy spontaneously or after ART: a systematic review and meta-analysis. Human Reproduction Update, 2020, 26, 514-544.	5.2	61
36	Initiation of Gonadotropin-Releasing Hormone Antagonist on Day 1 as Compared to Day 6 of Stimulation: Effect on Hormonal Levels and Follicular Development inin VitroFertilization Cycles. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5632-5637.	1.8	59

#	Article	IF	Citations
37	Thyroid function during ovarian stimulation: a systematic review. Fertility and Sterility, 2011, 96, 780-785.	0.5	58
38	Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial. Fertility and Sterility, 2011, 95, 558-562.	0.5	57
39	Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone. Fertility and Sterility, 2007, 88, 1382-1388.	0.5	56
40	Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial. Human Reproduction, 2016, 31, 977-985.	0.4	53
41	Is the use of donor sperm associated with a higher incidence of preeclampsia in women who achieve pregnancy after intrauterine insemination?. Fertility and Sterility, 2010, 93, 1124-1127.	0.5	51
42	Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability ofÂpregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial. Fertility and Sterility, 2011, 96, 1112-1115.	0.5	49
43	Spontaneous pregnancies in couples who discontinued intracytoplasmic sperm injection treatment: a 5-year follow-up study. Fertility and Sterility, 2002, 78, 550-556.	0.5	45
44	Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study. Reproductive Biology and Endocrinology, 2012, 10, 69.	1.4	40
45	Blastocyst culture: facts and fictions. Reproductive BioMedicine Online, 2002, 5, 285-293.	1.1	38
46	Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis. Fertility and Sterility, 2008, 90, 367-372.	0.5	38
47	Evidenceâ€based management of poor ovarian response. Annals of the New York Academy of Sciences, 2010, 1205, 199-206.	1.8	38
48	Cumulative delivery rates after ICSI treatment cycles with freshly retrieved testicular sperm: a 7-year follow-up study. Human Reproduction, 2003, 18, 1836-1840.	0.4	37
49	GnRH antagonists in IVF. Reproductive BioMedicine Online, 2005, 10, 705-712.	1.1	37
50	Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertility and Sterility, 2011, 95, 188-196.e3.	0.5	37
51	No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH. Reproductive BioMedicine Online, 2011, 23, 457-465.	1.1	37
52	Live birth rates using conventional in vitro fertilization compared to intracytoplasmic sperm injection in Bologna poor responders with a single oocyte retrieved. Journal of Assisted Reproduction and Genetics, 2015, 32, 691-697.	1.2	37
53	Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development. Human Reproduction, 2007, 22, 1540-1546.	0.4	36
54	Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial. Human Reproduction, 2015, 30, 432-440.	0.4	36

#	Article	IF	Citations
55	Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles. Human Reproduction, 2016, 31, 1859-1865.	0.4	36
56	Association of TSH Concentrations and Thyroid Autoimmunity with IVF Outcome in Women with TSH Concentrations within Normal Adult Range. Gynecologic and Obstetric Investigation, 2014, 77, 84-88.	0.7	34
57	Cumulative delivery rates after ICSI in women aged >37 years. Human Reproduction, 2002, 17, 940-944.	0.4	33
58	Effect of repeated assisted reproductive technology cycles on ovarian response. Fertility and Sterility, 2002, 77, 967-970.	0.5	33
59	Spontaneous triggering of ovulation versus HCG administration in patients undergoing IUI: a prospective randomized study. Reproductive BioMedicine Online, 2012, 25, 278-283.	1.1	33
60	The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation with progesterone or progesterone and estradiol. Fertility and Sterility, 2007, 87, 504-508.	0.5	32
61	Estrogen and folliculogenesis: is one necessary for the other?. Current Opinion in Obstetrics and Gynecology, 2005, 17, 249-253.	0.9	31
62	Association of the CYP2B6 c.516G>T Polymorphism with High Blood Propofol Concentrations in Women from Northern Greece. Drug Metabolism and Pharmacokinetics, 2014, 29, 215-218.	1.1	31
63	Vitamin D and Obesity: Two Interacting Players in the Field of Infertility. Nutrients, 2019, 11, 1455.	1.7	31
64	High exposure to progesterone between the end of menstruation and the day of triggering final oocyte maturation is associated with a decreased probability of pregnancy in patients treated by inÂvitro fertilization and intracytoplasmic sperm injection. Fertility and Sterility, 2011, 96, 884-888.	0.5	29
65	The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART. Human Reproduction Open, 2021, 2021, hoab022.	2.3	29
66	Is there an optimal number of oocytes retrieved at which live birth rates or cumulative live birth rates per aspiration are maximized after ART? A systematic review. Reproductive BioMedicine Online, 2021, 42, 83-104.	1.1	27
67	Serum vascular endothelial growth factor levels following luteal gonadotrophinâ€releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome. BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 848-855.	1.1	25
68	Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSI. Reproductive BioMedicine Online, 2003, 7, 313-318.	1.1	24
69	Thyroid autoimmunity and miscarriages: The corpus luteum hypothesis. Medical Hypotheses, 2009, 73, 1060-1062.	0.8	23
70	Quintuplet pregnancy following transfer of two blastocysts: Case report. Human Reproduction, 2004, 19, 325-327.	0.4	22
71	Duration of gonadotropin-releasing hormone antagonist administration does not affect the outcome of subsequent frozen-thawed cycles. Fertility and Sterility, 2004, 81, 473-475.	0.5	22
72	Association between vitamin D and endometriosis: a systematic review. Hormones, 2020, 19, 109-121.	0.9	21

#	Article	IF	Citations
73	Ovarian stimulation for inâ€fvitro fertilization in patients with endometriosis. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 651-655.	1.3	20
74	Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization. Fertility and Sterility, 2004, 82, 223-226.	0.5	20
75	Thyroid function and IVF outcome. Current Opinion in Obstetrics and Gynecology, 2016, 28, 191-197.	0.9	20
76	Emerging drugs in assisted reproduction. Expert Opinion on Emerging Drugs, 2005, 10, 425-440.	1.0	19
77	DHEA administration in poor responders. Human Reproduction, 2011, 26, 730-731.	0.4	19
78	Testicular versus ejaculated spermatozoa for ICSI in patients without azoospermia: A systematic review. Reproductive BioMedicine Online, 2018, 37, 573-580.	1.1	18
79	How frequent is severe ovarian hyperstimulation syndrome after GnRH agonist triggering in high-risk women? A systematic review and meta-analysis. Reproductive BioMedicine Online, 2021, 42, 635-650.	1.1	18
80	Higher ovulation rate with letrozole as compared with clomiphene citrate in infertile women with polycystic ovary syndrome: a systematic review and meta-analysis. Hormones, 2021, 20, 449-461.	0.9	18
81	Blastocyst Development in a Single Medium Compared to Sequential Media: A Prospective Study With Sibling Oocytes. Reproductive Sciences, 2017, 24, 1312-1318.	1.1	17
82	Is the time interval between HCG administration and oocyte retrieval associated with oocyte retrieval rate?. Reproductive BioMedicine Online, 2015, 31, 625-632.	1.1	16
83	Propofol versus thiopental sodium as anaesthetic agents for oocyte retrieval: a randomized controlled trial. Reproductive BioMedicine Online, 2015, 31, 752-759.	1.1	16
84	Outcome for donors and recipients in two egg-sharing policies. Fertility and Sterility, 2003, 79, 69-73.	0.5	15
85	Hysteroscopic septum resection using the Versapoint system in subfertile women. Reproductive BioMedicine Online, 2003, 7, 365-367.	1.1	15
86	Is it possible to reduce the incidence of weekend oocyte retrievals in GnRH antagonist protocols?. Reproductive BioMedicine Online, 2013, 26, 50-58.	1.1	13
87	Blastocyst utilization rates after continuous culture in two commercial single-step media: a prospective randomized study with sibling oocytes. Journal of Assisted Reproduction and Genetics, 2017, 34, 1377-1383.	1.2	12
88	Egg freezing and late motherhood. Maturitas, 2019, 125, 1-4.	1.0	12
89	Achievement of pregnancy three times in the same patient during luteal GnRH agonist administration. Reproductive BioMedicine Online, 2005, 10, 347-349.	1.1	11
90	Role of the endocrine profile for the achievement of pregnancy with IVF. Reproductive BioMedicine Online, 2009, 18, S37-S43.	1.1	11

#	Article	IF	Citations
91	Sociocultural influences on fertility in the Middle East: the role of parental consanguinity, obesity and vitamin D deficiency. Fertility and Sterility, 2016, 106, 259-260.	0.5	11
92	Relationship between LH and oestradiol in IVF cycles before GnRH antagonist initiation. Reproductive BioMedicine Online, 2003, 7, 190-193.	1.1	10
93	GnRH antagonists in poor responders. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 1216-1217.	1.3	10
94	Effects of Different Drug Therapies and COVID-19 mRNA Vaccination on Semen Quality in a Man with Ankylosing Spondylitis: A Case Report. Medicina (Lithuania), 2022, 58, 173.	0.8	10
95	Cumulative live birth rates after transfer of cryopreserved ICSI embryos. Reproductive BioMedicine Online, 2004, 8, 344-348.	1.1	9
96	Does hyaluronan improve embryo implantation?. Current Opinion in Obstetrics and Gynecology, 2008, 20, 305-307.	0.9	9
97	Association between body mass index and oocyte maturation in patients triggered with GnRH agonist who are at high risk for severe ovarian hyperstimulation syndrome: an observational cohort study. Reproductive BioMedicine Online, 2020, 40, 168-175.	1.1	9
98	EMAS position statement: Late parenthood. Maturitas, 2013, 76, 200-204.	1.0	8
99	Effects of vitrification on blastomere viability and cytoskeletal integrity in mouse embryos. Zygote, 2017, 25, 75-84.	0.5	8
100	Ovarian tissue cryopreservation and transplantation to delay menopause: facts and fiction. Maturitas, 2020, 142, 64-67.	1.0	8
101	Complex chromosomal aberrations in a fetus originating from oocytes with smooth endoplasmic reticulum (SER) aggregates. Systems Biology in Reproductive Medicine, 2018, 64, 283-290.	1.0	7
102	GnRH antagonists in poor responders. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 1216-1217.	1.3	7
103	Is assessment of anti-mullerian hormone and/or antral follicle count useful in the prediction of ovarian response in expected normal responders treated with a fixed dose of recombinant FSH and GnRH antagonists? A prospective observational study. Gynecological Endocrinology, 2014, 30, 817-821.	0.7	6
104	GnRH antagonists vs. long GnRH agonists in IVF: significant flaws in a meta-analysis lead to invalid conclusions. Human Reproduction Update, 2018, 24, 242-243.	5.2	6
105	No decrease occurs in the number of COCs retrieved with repeated IVF cycles. Human Reproduction, 2004, 19, 1927-1928.	0.4	5
106	Thyroid function and autoimmunity during ovarian stimulation for intracytoplasmic sperm injection. Reproduction, Fertility and Development, 2017, 29, 603.	0.1	5
107	Follicle inhibition at the primordial stage without increasing apoptosis, with a combination of everolimus, verapamil. Molecular Biology Reports, 2020, 47, 8711-8726.	1.0	5
108	Prenatal genetic testing by amniocentesis appears to result in a lower risk of fetal loss than chorionic villus sampling in singleton pregnancies achieved by intracytoplasmic sperm injection. Fertility and Sterility, 2003, 79, 374-378.	0.5	4

#	Article	IF	Citations
109	In Vitro Fertilization With Single Blastocyst-Stage versus Single Cleavage-Stage Embryos. Obstetrical and Gynecological Survey, 2006, 61, 523-525.	0.2	4
110	Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists. Human Reproduction, 2006, 21, 1012-1017.	0.4	4
111	Elimination of OHSS by GnRH Agonist and Freezing Embryos. , 0, , 149-163.		4
112	Decline in anti-MÃ¼llerian hormone concentrations following radioactive iodine treatment in women with differentiated thyroid cancer: A systematic review and meta-analysis. Maturitas, 2021, 148, 40-45.	1.0	4
113	Expression of genes that regulate follicle development and maturation during ovarian stimulation in poor responders. Reproductive BioMedicine Online, 2021, 42, 248-259.	1.1	4
114	Female Infertility and Cardiovascular Risk - A Hype or an Underestimated Reality?. Current Pharmaceutical Design, 2020, 26, 5551-5555.	0.9	4
115	Increasing survival of the graft: the way forward in ovarian tissue transplantation. Reproductive BioMedicine Online, 2015, 30, 4-5.	1.1	3
116	Addition of procyanidine to semen preserves progressive sperm motility up to three hours of incubation. Reproductive Biology, 2019, 19, 255-260.	0.9	3
117	Spindle and chromosome configuration analysis of human biopsied versus non-biopsied embryos by confocal laser scanning microscopy following vitrification. Zygote, 2019, 27, 153-159.	0.5	3
118	The human embryo following biopsy on day 5 vs day 3: viability, ultrastructure and spindle / chromosomes configurations. Reproductive BioMedicine Online, 2022, , .	1.1	3
119	A case of Adams-Oliver syndrome following in vitro fertilization. Human Reproduction, 2009, 24, 1529-1530.	0.4	2
120	GnRH-antagonists in ovarian stimulation for IVF. , 2012, , 124-130.		2
121	Is Hysteroscopy Prior to IVF Associated with an Increased Probability of Live Births in Patients with Normal Transvaginal Scan Findings after Their First Failed IVF Trial?. Journal of Clinical Medicine, 2022, 11, 1217.	1.0	2
122	Limits of agreement?. Fertility and Sterility, 2004, 82, 1475-1476.	0.5	1
123	The effect of oral contraceptives on assisted reproductive technology cycles. Current Opinion in Obstetrics and Gynecology, 2007, 19, 244-247.	0.9	1
124	Reply of the Authors. Fertility and Sterility, 2014, 101, e5-e6.	0.5	1
125	Role of Agonists and Antagonists in COS. , 2018, , 16-19.		1
126	Is in vitro fertilization an indication for fetal echocardiography?. Fertility and Sterility, 2021, 116, 676-677.	0.5	1

#	Article	IF	Citations
127	Is addressing the needs of its membership an easy task for the American Society for Reproductive Medicine?. Fertility and Sterility, 2004, 82, 555-556.	0.5	0
128	Reply: Modified natural cycle IVF for poor responders. Human Reproduction, 2005, 20, 2661-2662.	0.4	0
129	Triggering of final oocyte maturation in ovarian stimulation. , 0, , 233-243.		0
130	Ovulation Induction and Assisted Reproduction. , 2010, , 2407-2416.		0
131	Barriers to conducting clinical research in reproductive medicine: Greece. Fertility and Sterility, 2011, 96, 807-808.	0.5	0
132	GnRH antagonists in ART. , 0, , 73-79.		0
133	Reply: Modified natural cycles for poor responders: addressing misconceptions and fallacies. Human Reproduction, 2016, 31, 222-223.	0.4	0
134	Ovarian Hyperstimulation Syndrome. , 2019, , 581-587.		0
135	GnRH Agonists and Antagonists. , 2019, , 59-68.		0
136	Pituitary Suppression Using GnRH Agonist for IVF Is Outdated. , 2021, , 216-218.		0